Pomalyst (pomalidomide) is a prescription drug that’s used to treat multiple myeloma in adults. Pomalyst is also available as a generic drug. Pomalyst comes as an oral capsule. The active ...

In conclusion, the editorial underscores the potential of pomalidomide as a key player in the treatment of multiple myeloma. By enhancing the immune function and improving progression-free ...

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

The authors explain that adding pomalidomide to standard treatments may help strengthen the immune system and improve patient outcomes. Multiple myeloma affects plasma cells in the bone marrow.

Pomalidomide is a highly potent third-generation ... the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

The treatment landscape for multiple myeloma is evolving rapidly ... phase I/II trial evaluated lisaftoclax in combination with pomalidomide (Pomalyst) and dexamethasone (PD) or daratumumab ...

CARTITUDE-4 compared Carvykti to a pair of three-drug multiple myeloma regimens – pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd ...

pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM). Dr Richter explains which patients would benefit the ...